Evvy is a precision women’s health company that’s reshaping how vaginal and reproductive health is understood and managed. Pulse 2.0 interviewed Evvy co-founder and CEO Priyanka Jain to gain a deeper understanding of the company.
Priyanka Jain’s Background
Could you tell me more about your background? Jain said:
“I’ve spent my career at the intersection of data, product, and equity. Before founding Evvy, I was Head of Product at Pymetrics, a startup using neuroscience and AI to make hiring more equitable. We raised $70 million, worked with Fortune 500s, and passed landmark legislation on bias in AI. But I’ve actually been working on girls’ and women’s issues since I was a teenager—I helped launch the UN Foundation’s Girl Up campaign and later led Stanford Women in Business. Evvy brings those threads together: tech-driven innovation and a lifelong mission to close the gender health gap.”
Formation Of The Company
How did the idea for the company come together? Jain shared:
“It was a mix of personal frustration and professional curiosity. Despite years in data and AI, I couldn’t get answers for my own chronic health issues. I realized we weren’t running the right tests because we weren’t collecting the right data—especially for women. Through research and dozens of conversations with doctors and scientists, I discovered that the vaginal microbiome was both massively overlooked and incredibly important. That became the foundation for Evvy. I teamed up with my co-founders Laine and Pita, and we built a company to close the gender health gap through novel biomarker discovery—starting with the vaginal microbiome.”
Favorite Memory
What has been your favorite memory working for the company so far? Jain reflected:
“There’s nothing like reading the messages from women who say, ‘Evvy saved my life.’ These are people who’ve been dismissed or misdiagnosed for years, and for the first time, they feel like their symptoms make sense. That feedback is the most meaningful thing to me—it’s why we do this.”
Core Products
What are the company’s core products and features? Jain explained:
“Our platform starts with the Evvy Vaginal Health Test, the first CLIA/CAP/CLEP-certified, at-home vaginal microbiome test using metagenomic sequencing. It detects 700+ microbes with a single swab and gives users personalized insights and next steps. We also offer STI + antibiotic resistance testing, 1:1 health coaching, and clinician-led clinical care, including custom-compounded prescription treatments. It’s the first platform to combine testing, diagnosis, and precision treatment in one seamless experience. Our care can be delivered via Evvy’s providers or a user’s own doctor. The entire platform is tech-first, validated, and designed to scale.”
Challenges Faced
Have you faced any challenges in your sector of work recently? Jain acknowledged:
“Absolutely. Vaginal health is still considered taboo, underfunded, and misunderstood. We’ve had to educate consumers, investors, and even clinicians on why it matters. Reimbursement is a huge hurdle—many payers still don’t cover comprehensive vaginal health testing, even though it could drastically improve outcomes and reduce long-term healthcare costs. But we’ve overcome those barriers through rigorous science, real-world outcomes, and relentless advocacy.”
Evolution Of The Company’s Technology
How has the company’s technology evolved since launching? Jain noted:
“When we launched in 2021, we focused on delivering the first at-home vaginal microbiome test using metagenomic sequencing. Today, our platform includes a bioinformatics pipeline, multiple AI-driven recommendation engines, and the proprietary SAGE database—where we’ve identified 2x more vaginal genomes than had previously been documented. We’ve moved from being a test to a full-stack precision care platform.”
Significant Milestones
What have been some of the company’s most significant milestones? Jain cited:
“We started in 2021 by launching the world’s first at-home, metagenomics-based vaginal microbiome test. Since then, we’ve expanded to end-to-end clinical care, STI and antibiotic resistance testing, and AI-powered personalization tools. We’ve published our data in many peer-reviewed journals (including validation of our test and care platform) and presented at clinical conferences across the country.”
“We’ve also served over 50,000 patients and built the world’s largest real-world dataset on the vaginal microbiome, allowing us to constantly refine our predictions and uncover new biomarkers for fertility, pregnancy, cancer, and more.”
Customer Success Stories
When asking Jain about customer success stories, she highlighted:
“We regularly hear from users who’ve suffered for years—some with symptoms dismissed as ‘normal’ or ‘just hormonal’—and finally found clarity and relief through Evvy. One patient wrote, “After decades of confusion, Evvy gave me a diagnosis in days. For the first time, I feel like my body makes sense.” In our IRB-approved study, 83% of patients went from dysbiosis to a protective microbiome in just 2 months, and 100% reported symptom improvement.”
Funding
When asking Jain about the company’s funding details, she revealed:
“Yes. Evvy has raised over $20 million to date, including a $14 million Series A in 2023.”
Total Addressable Market
What total addressable market (TAM) is the company pursuing? Jain assessed:
“The vaginal health category alone accounts for $7B in annual spending. But the vaginal microbiome also plays a role in IVF failure, preterm birth, STI acquisition, endometriosis, and cancer progression — expanding our TAM to more than $115 billion.”
Differentiation From The Competition
What differentiates the company from its competition? Jain affirmed:
“Evvy is the only company offering:
- CLIA/CAP/CLEP-certified metagenomic sequencing of the vaginal microbiome
- Peer-reviewed test validation
- Proprietary reference genome database (SAGE)
- Personalized, integrative care with licensed providers (custom-compounded Rx treatments)
Competitors use less comprehensive testing methods (like 16S or PCR-only), lack clinical validation, and don’t offer end-to-end care. Evvy is built to deliver not just data, but precision care.”
Future Company Goals
What are some of the company’s future goals? Jain emphasized:
“In 2025 and beyond, we’re focused on:
- Expanding our test & care platform for patients and providers
- Scaling our impact in fertility and pregnancy
- Discovering novel biomarkers for improved diagnostics & therapeutics in women’s health”
Additional Thoughts
Any other topics you’d like to discuss? Jain concluded:
“Vaginal health is just the beginning. Our goal is to transform how we define, diagnose, and treat disease in the female body. We’re building the datasets that precision medicine needs for women — and we’re doing it from the ground up, with patients at the center.”
